324 / 604
SUMMARY 2
MSCC
RS / SBRT
conv.
RT
Improvement, less selected:
23%
40%
Improvement, myeloma:
71%
76%
Improvement, ambulatory:
63%
62%
Potential Benefit of RS / SBRT for:
►
Long-term Survivors (SBRT instead of RS to reduce late
toxicity)
►
Less Radiosensitive Tumors
►
Re-RT, in particular after previous longer-course RT